Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy - Trial NCT05941169
Access comprehensive clinical trial information for NCT05941169 through Pure Global AI's free database. This phase not specified trial is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 750 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Timeline & Enrollment
N/A
Aug 01, 2023
Apr 01, 2031
Primary Outcome
Overall Survival
Summary
The benefit of deferred Cytoreductive Nephrectomy (CN) has to be re-assessed in the context
 of IO +IO and IO + TKI systemic treatment. Given the benefit of CN in the setting of first
 generation immunotherapy, it is conceivable that both trials underestimated the benefit of
 CN, in absence of immunotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05941169
Non-Device Trial